Medical NewsGerman Drug Data (Deutsch)
Norwegian Drug Data (Norge)
Netherlands Drug Data (Nederlands)
Swedish Drug Data (Sverige)
Want to submit or suggest content for the epgonline.org YouTube Clinical channel?
Contact us here
epgonline.org is not responsible for content on any 3rd party website
Please register to access disease diagnosis, patient management, physician tools.
By viewing the content of this web page you are both confirming your status as a healthcare professional and agreeing to our terms of use.
| Drug class description : | Enzymes |
| Generic Name : | Rasburicase |
| Drug description : | Powder and solvent for concentrate for solution for infusion. Rasbururicase is a recombinant urate-oxidase enzyme produced by genetically modified Saccharomyces cerevisiae strain. |
| Presentation : | Powder for concentrate for solution for infusion, rasburicase 1.5mg. 1ml of concentrate contains rasburicase 1.5mg. |
| Indications : | Treatment and prophylaxis of acute hyperuricaemia, in order to prevent acute renal failure, in patients with haematological malignancy with a high tumor burden and at risk of a rapid tumor lysis or shrinkage at initiation of chemotherapy. |
| Adult Dosage : | Recommended dose, 0.20mg/kg/day as a once daily 30 minute intravenous infusion in 50ml of 0.9% w/v sodium chloride solution. The duration of treatment may vary between five and seven days. Fasturtec is to be used immediately prior to and during the intiation of chemotherapy only; currently, there are insufficient data to recommend multiple treatment courses. |
| Contra Indications : | Hypersensitivity to uricases or any of the excipients. G6PD deficiency and other cellular metabolic disorders known to cause haemolytic anaemia induced by hydrogen peroxide, rasburicase is contraindicated in patients with these disorders. Pregnancy and lactation. |
| Special Precautions : | To be administered under the supervision of a physician trained in chemotherapy of haematological malignancies. Monitor patients closely for the onset of allergic-type undesirable effects., especially skin allergic reaction or bronchospasm; discontinue treatment if any serious allergic or anaphylactic reaction occurs. History of atopic allergies. Currently, insufficient data to recommend multiple treatment courses. Monitor patients closely for hyperphosphataemia, hyperkalaemia amd hyperuricaemia in the context of myeloproliferative disorders. There are no data available to recommend the sequential use of resburicase and allopurinol. |
| Interactions : | No metabolism studies have been carried out. Drug-drug interactions unlikely. |
| Adverse Reactions : | Most commonly, fever, vomiting, nausea. Uncommonly, diarrhoea, headache, allergic reactions (including bronchospasm), rash. |
| Manufacturer : | Sanofi-Synthelabo |
| Drug Availability : | (POM) |
Only registered users have access to the full EPG Online Knowledge Base including drug search tools, interactive disease Knowledge Centres via the EPG Knowledge Library - with clinical and evidence based physician and research tools, MiMedia (build your own clinical media collection with everything from key opinion leader essays to mode of action videos and other multi-media content), the EPG Survey panel, health news updates and much much more.
Already Registered?
Please log-in now using our member login box.
Not a member?
Don't worry, registration is quick and FREE! We welcome all Healthcare professionals, doctors, nurses and medical students.
Register today to have full access to a wealth of drug data, educational and evidence based interactive guides across all major therapeutic areas, disease management, and clinical tools.
As a practicing Healthcare professional, you can also opt-in to join our market research panel – www.epgsurvey.com – and get paid for sharing your expert clinical opinions!
REGISTER today it only takes a minute! and it's FREE
Having problems?
Use our forgotten password facility or email us at: contact@epgonline.org